Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid
Executive Summary
The pharma hopes showing a PFS benefit in first-line NSCLC patients with a high tumor mutation burden may provide a way to compete with Merck in that setting, but analysts think it will need overall survival data.
You may also be interested in...
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Merck's Keytruda Keeps Nipping At Opdivo's Heels
In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.